In malignant melanoma, the high level of AXL is mostly associated with the mesenchymal cell state, leading to enhanced resistance to targeted therapy, such as MAPK inhibitors in the case of malignant melanoma [66,67] and endothelial growth factor receptor (EGFR) inhibitors in case of lung cancer. Here, EGFR is linked to melanoma.